Skip to main content
      RT @ejdein1: Seeing the sites of Paris at virtual #eular2021. Follow on @RheumNow along with @RichardPAConway @MeralElRa

      Eric Dein ejdein1

      4 years 5 months ago
      Seeing the sites of Paris at virtual #eular2021. Follow on @RheumNow along with @RichardPAConway @MeralElRamahiMD @Yuz6Yusof @Stiddyo @KDAO2011 @uptoTate @AurelieRheumo @drdavidliew @Janetbirdope https://t.co/w18REG08nz
      RT @AurelieRheumo: @RheumNow I will be tweeting alongside an amazing team @RichardPAConway @MeralElRamahiMD @Stiddyo @KD

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      @RheumNow I will be tweeting alongside an amazing team @RichardPAConway @MeralElRamahiMD @Stiddyo @KDAO2011 @uptoTate @Yuz6Yusof @drdavidliew @ejdein1 @Janetbirdope @TammyTilley & last but not least Dr Cush! Follow them and @Rheumnow to stay tuned for the latest science! #EULAR2021
      RT @RichardPAConway: There seem to be quite a few #EULAR2021 abstracts that are identical (or nearly) to #ACR20 abstract

      Richard Conway RichardPAConway

      4 years 5 months ago
      There seem to be quite a few #EULAR2021 abstracts that are identical (or nearly) to #ACR20 abstracts, eg mavrilimumab and GUSTO in vasculitis oral presentation section. Have the rules changed?
      RT @doctorRBC: Guselkumab (IL-23i) 52 week extension study in PsA pts from DISCOVER 1 and 2⭐️sustained DAPSA LDA/re

      Robert B Chao, MD doctorRBC

      4 years 5 months ago

      Guselkumab (IL-23i) 52 week extension study in PsA pts from DISCOVER 1 and 2 ⭐️sustained DAPSA LDA/remission ⭐️sustained PASDAS LDA/vLDA ⭐️sustained MDA POS1024 #EULAR2021 @RheumNow

      RT @doctorRBC: C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA
      ⭐️82% ⬇️ in uveitis flare ev

      Robert B Chao, MD doctorRBC

      4 years 5 months ago
      C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA ⭐️82% ⬇️ in uveitis flare event ⭐️reduction in axSpA disease activity ⭐️no new safety signals POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY
      RT @KDAO2011: Longitudinal UK SLE inception cohort 273 pts found:
      👉⬆️damage in 1st 3 yrs b/f stabilizing at lower

      k dao KDAO2011

      4 years 5 months ago
      Longitudinal UK SLE inception cohort 273 pts found: 👉⬆️damage in 1st 3 yrs b/f stabilizing at lower rate 👉mortality uncommon in 1st 12 yrs, but can occur w/in 5 yrs of Dx. 👉unexpected⬆️mortality in Caucasians 38% deaths IHD, 23% infx Abst#0111 #EULAR2021 @rheumnow @Lupusdoc https://t.co/wUwWaB4V2R
      RT @KDAO2011: Can you predict flares in SLE pts who achieved LLDAS?Retrospec cohort study from Portugal over 3 years of

      k dao KDAO2011

      4 years 5 months ago

      Can you predict flares in SLE pts who achieved LLDAS? Retrospec cohort study from Portugal over 3 years of 292 pts who were in LLDAS, 31% flared. Flares seen more in: 👉pts who require ongoing Rx w/ immmunosuppr, GCs 👉pt w/+RNP Abst#0105 #EULAR2021 @RheumNow https://t.co/xfBqGh4pPP

      RT @KDAO2011: C3 and C4⬆️in SLE pregnancy like they would in pregnancies w/o SLE!
      French GR2 prospective study of 29

      k dao KDAO2011

      4 years 5 months ago
      C3 and C4⬆️in SLE pregnancy like they would in pregnancies w/o SLE! French GR2 prospective study of 290 SLE pregnancies quantifies mean C3 value⬆️by 28%, C4⬆️by 11% from 1st ➡️3rd trimester. Remember this when assessing disease activity. #EULAR2021 Abstr #0103 @rheumnow https://t.co/TXjO4mjNJE
      RT @KDAO2011: Definition of LLDAS: "A state assc w/low likelihood of adverse outcome, considering disease activity and m

      k dao KDAO2011

      4 years 5 months ago
      Definition of LLDAS: "A state assc w/low likelihood of adverse outcome, considering disease activity and medication safety; it must be favorable, deployable, feasible, and attainable," - Dr. E Morand #EULAR2021 @RheumNow https://t.co/oMMU3AjhmX
      RT @uptoTate: Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically i

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically in a meaningful way. Some key SpA/PsA findings from the experts at ASRI and the CorEvitas registry @rheumnow https://t.co/irxQs7Yzrx
      RT @KDAO2011: Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk
      👉Hormones drive funx change in T

      k dao KDAO2011

      4 years 5 months ago
      Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk 👉Hormones drive funx change in Treg transciptome 👉anti-inflamm Tregs⬆️in males 👉Tregs are more suppressive in males 👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK
      RT @uptoTate: In DESIR AxSpA cohort: only 25% of patients achieved remission at 5 year follow up!!! Lower SES and ^ weig

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      In DESIR AxSpA cohort: only 25% of patients achieved remission at 5 year follow up!!! Lower SES and ^ weight were negative factors in remission. Abstract #OP0052 #EULAR2021 @RheumNow https://t.co/X4wN1wIGfX https://t.co/DKBIXmEmki
      RT @uptoTate: Female AxSpA pts report worse PROs but have better spinal mobility vs male AxSpA pts. Dz activity pattern

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      Female AxSpA pts report worse PROs but have better spinal mobility vs male AxSpA pts. Dz activity pattern similar in 4/6 BASDAI components regardless of gender. Females reports ^ fatigue, males report ^ spinal pain. Abstract# OP0051 #EULAR2021 @RheumNow https://t.co/U8T8JEWwCp https://t.co/yNP6PuA8PD
      RT @KDAO2011: ProDERM study (95 pts): RBPCT phase III IVIG 10% is effective in dermatomyositis (2 g/kg over 2-5 days q4

      k dao KDAO2011

      4 years 5 months ago
      ProDERM study (95 pts): RBPCT phase III IVIG 10% is effective in dermatomyositis (2 g/kg over 2-5 days q4 weeks. (common AEs: HA, fever, nausea most common AEs, rare SAE include thrombosis, LoC, hypoesthesia). Dr. R Aggarwal Abstr#OP008 #EULAR2021 @RheumNow https://t.co/ScTdUySxOl
      RT @KDAO2011: Put out cigarettes around others!
      👉passive smoking in childhood & adulthood⬆️RA risk
      👉RA oc

      k dao KDAO2011

      4 years 5 months ago
      Put out cigarettes around others! 👉passive smoking in childhood & adulthood⬆️RA risk 👉RA occurs earlier for passive smoking in childhood 👉passive smoking can cause citrullination in genetically proned subjects b/f 1st Sx's Dr. Y Nguyen Abstr#OP0012 #EULAR2021 @rheumnow https://t.co/ZoIumNQQAf
      ×